Skip to main content
Fig. 3 | BMC Pulmonary Medicine

Fig. 3

From: Clinical effects of direct hemoperfusion using a polymyxin B-immobilized fiber column in clinically amyopathic dermatomyositis-associated rapidly progressive interstitial pneumonias

Fig. 3

Clinical parameters differences before and after PMX-DHP in the survivor and non-survivor groups. a: White blood cell counts, b: neutrophil counts, c: platelet counts, d: serum LDH levels, e: serum HMGB-1 levels, f: and P/F ratio in the survivor (solid line and closed circles) and non-survivor (dotted line and closed squares) groups after PMX-DHP therapy. In the survivor group, serum LDH levels, serum HMGB-1 levels, and WBC, neutrophil, and platelet counts tended to decrease after PMX-DHP therapy, but there were no significant differences between the survivor and non-survivor groups

Back to article page